GlassScriptPhysician profile
Leslie M Phillips
NPI 1851896260
$9,258.04
in general payments reported to CMS, 2019-2025
51 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,924 · 2022: $1,962 · 2023: $1,920 · 2024: $1,950 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,372.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,978.70 | 2021-2025 | |
| Lilly USA, LLC | $821.43 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $784.54 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $640.32 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $619.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $510.52 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $396.74 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $308.87 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.90 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $200.88 | 2021-2024 | |
| Pfizer INC. | $199.66 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.04 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $182.59 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.45 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $139.88 | 2025 | Auvelity, Sunosi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.